Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type

NCT02967497 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER_GOV

Sponsor class

Conditions

Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer

Interventions

DRUG: YQ1

Sponsor

Taipei Veterans General Hospital, Taiwan

Collaborators

[object Object]